Out-licensed to Novo Nordisk A/S

IPH 2201 is a monoclonal antibody which therapeutic principle is comparable to that of IPH 2101: the goal is to block another inhibitory receptor that is present on a subpopulation of NK cells, on NKT cells and certain T lymphocytes.

 
IPH 2201 is developed in inflammatory conditions and autoimmune diseases by Novo Nordisk A/S.